

Jin Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3804797/publications.pdf>

Version: 2024-02-01

127
papers

6,101
citations

87888

38
h-index

95266

68
g-index

130
all docs

130
docs citations

130
times ranked

7237
citing authors

#	ARTICLE	IF	CITATIONS
1	Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. <i>Molecular Cancer</i> , 2021, 20, 131.	19.2	702
2	Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. <i>Journal of Hematology and Oncology</i> , 2020, 13, 110.	17.0	698
3	Applications of single-cell sequencing in cancer research: progress and perspectives. <i>Journal of Hematology and Oncology</i> , 2021, 14, 91.	17.0	172
4	The microbiota and microbiome in pancreatic cancer: more influential than expected. <i>Molecular Cancer</i> , 2019, 18, 97.	19.2	169
5	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. <i>Molecular Cancer</i> , 2020, 19, 49.	19.2	145
6	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. <i>Theranostics</i> , 2018, 8, 5072-5087.	10.0	139
7	Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 561-568.	1.5	137
8	Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. <i>International Journal of Cancer</i> , 2017, 140, 2344-2350.	5.1	133
9	Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. <i>Journal of Clinical Oncology</i> , 2017, 35, 274-280.	1.6	124
10	ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. <i>Cell Research</i> , 2015, 25, 561-573.	12.0	112
11	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. <i>Experimental and Molecular Medicine</i> , 2017, 49, e406-e406.	7.7	108
12	Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China. <i>Cancer Letters</i> , 2014, 346, 273-277.	7.2	107
13	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. <i>Cancer Letters</i> , 2016, 374, 127-135.	7.2	104
14	A miR-146a-5p/TRAF6/NF- κ B p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. <i>Theranostics</i> , 2020, 10, 3967-3979.	10.0	103
15	Localisation of PCK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. <i>Gut</i> , 2020, 69, 888-900.	12.1	99
16	Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4591-4598.	2.0	92
17	Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3 β /Snail signaling. <i>Oncogene</i> , 2018, 37, 5843-5857.	5.9	92
18	TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. <i>Autophagy</i> , 2020, 16, 486-500.	9.1	73

#	ARTICLE	IF	CITATIONS
19	FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3950-3960.	7.0	72
20	PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. <i>Cell Communication and Signaling</i> , 2019, 17, 30.	6.5	72
21	Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 944-950.	4.2	71
22	Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. <i>Oncotarget</i> , 2016, 7, 5943-5956.	1.8	70
23	Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. <i>Theranostics</i> , 2021, 11, 2755-2769.	10.0	64
24	LSD1 sustains pancreatic cancer growth via maintaining HIF1 α -dependent glycolytic process. <i>Cancer Letters</i> , 2014, 347, 225-232.	7.2	63
25	The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. <i>PeerJ</i> , 2020, 8, e9602.	2.0	62
26	KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. <i>Cancer Letters</i> , 2019, 446, 103-111.	7.2	57
27	The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. <i>Pancreatology</i> , 2016, 16, 1080-1084.	1.1	56
28	Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. <i>Abdominal Imaging</i> , 2009, 34, 759-766.	2.0	55
29	The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. <i>Molecular Cancer</i> , 2019, 18, 184.	19.2	54
30	The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1347-1347.	1.7	53
31	Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. <i>Surgery</i> , 2017, 161, 373-384.	1.9	49
32	New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. <i>Pancreatology</i> , 2018, 18, 971-976.	1.1	47
33	Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	47
34	ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. <i>Cancer Letters</i> , 2017, 388, 303-311.	7.2	46
35	Role of angiogenesis in pancreatic cancer biology and therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1135-1140.	5.6	46
36	PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. <i>Cancer Research</i> , 2019, 79, 133-145.	0.9	46

#	ARTICLE	IF	CITATIONS
37	Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Research</i> , 2017, 15, 201-212.	3.4	45
38	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1 α axis and indicates prognosis in pancreatic cancer. <i>Cell Death and Disease</i> , 2018, 9, 321.	6.3	45
39	Hypoxia: a barricade to conquer the pancreatic cancer. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3077-3083.	5.4	45
40	Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. <i>Molecular Cancer</i> , 2021, 20, 106.	19.2	45
41	New insights into perineural invasion of pancreatic cancer: More than pain. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 111-122.	7.4	39
42	Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. <i>Pancreatology</i> , 2014, 14, 295-301.	1.1	38
43	Surgery management for sporadic small (≤ 2 cm), non-functioning pancreatic neuroendocrine tumors: A consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). <i>International Journal of Oncology</i> , 2017, 50, 567-574.	3.3	38
44	Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. <i>Cancer Letters</i> , 2015, 360, 227-233.	7.2	37
45	GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. <i>Cell Death and Disease</i> , 2018, 9, 1187.	6.3	37
46	Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. <i>Pancreatology</i> , 2016, 16, 1057-1062.	1.1	36
47	A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. , 2019, 7, 233.		34
48	Rotavirus and coxsackievirus infection activated different profiles of toll-like receptors and chemokines in intestinal epithelial cells. <i>Inflammation Research</i> , 2009, 58, 585-592.	4.0	33
49	Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 648917.	4.8	33
50	Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors. <i>Oncology Letters</i> , 2017, 13, 2454-2458.	1.8	32
51	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 1001-1012.	5.4	31
52	Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10944.	4.1	30
53	Epithelial \rightarrow mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 43-49.	7.4	29
54	Homeodomain \rightarrow interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. <i>Cell Proliferation</i> , 2019, 52, e12603.	5.3	29

#	ARTICLE	IF	CITATIONS
55	The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 271, 559-565.	4.2	29
56	Emerging roles of the solute carrier family in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e356.	4.0	29
57	Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. <i>International Journal of Molecular Sciences</i> , 2017, 18, 81.	4.1	28
58	The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives. <i>Journal of Hematology and Oncology</i> , 2020, 13, 154.	17.0	28
59	The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context. <i>Frontiers in Oncology</i> , 2022, 12, 862743.	2.8	28
60	The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: Two years of the COVID-19 pandemic. <i>Journal of Medical Virology</i> , 2022, 94, 4696-4703.	5.0	28
61	Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET). <i>International Journal of Oncology</i> , 2016, 49, 1991-2000.	3.3	27
62	Critical role of oncogenic KRAS in pancreatic cancer (Review). <i>Molecular Medicine Reports</i> , 2016, 13, 4943-4949.	2.4	27
63	Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). <i>BMJ Open</i> , 2019, 9, e033452.	1.9	27
64	Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. <i>American Journal of Cancer Research</i> , 2018, 8, 332-353.	1.4	27
65	Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. <i>Radiation Oncology</i> , 2015, 10, 14.	2.7	26
66	Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 $\geq 1,000$ U/mL. <i>Scientific Reports</i> , 2016, 6, 19222.	3.3	26
67	Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. <i>Cancer Medicine</i> , 2020, 9, 2153-2159.	2.8	26
68	Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. <i>International Journal of Oncology</i> , 2013, 42, 2046-2052.	3.3	24
69	Energy sources identify metabolic phenotypes in pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 969-979.	2.0	24
70	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. <i>Oncology Reports</i> , 2017, 38, 2069-2077.	2.6	23
71	MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. <i>International Journal of Cancer</i> , 2018, 143, 2919-2931.	5.1	23
72	Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1247.	4.3	22

#	ARTICLE	IF	CITATIONS
73	<scp>dCK</scp> negatively regulates the <scp>NRF</scp>2/<scp>ARE</scp> axis and <scp>ROS</scp> production in pancreatic cancer. <i>Cell Proliferation</i> , 2018, 51, e12456.	5.3	22
74	Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. <i>Surgery</i> , 2015, 158, 1211-1218.	1.9	21
75	RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. <i>Oncogene</i> , 2022, 41, 2860-2872.	5.9	21
76	A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. <i>International Journal of Oncology</i> , 2017, 50, 1792-1800.	3.3	20
77	Carbohydrate antigen 19â€™9 as a prognostic biomarker in pancreatic neuroendocrine tumors. <i>Oncology Letters</i> , 2017, 14, 6795-6800.	1.8	20
78	Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Cancer</i> , 2017, 8, 3615-3622.	2.5	20
79	A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. <i>Surgery</i> , 2018, 163, 1280-1294.	1.9	20
80	Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. <i>Journal of Cancer</i> , 2019, 10, 4420-4429.	2.5	20
81	Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5505-5526.	5.4	20
82	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 177-188.	7.4	18
83	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. <i>Cancer Cell International</i> , 2021, 21, 196.	4.1	18
84	Enhancement of Mucosal and Cellular Immune Response in Mice by Vaccination with Respiratory Syncytial Virus DNA Encapsulated with Transfersome. <i>Viral Immunology</i> , 2008, 21, 483-490.	1.3	17
85	Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. <i>Pancreatology</i> , 2015, 15, 253-258.	1.1	17
86	Strategies for pancreatic anastomosis after pancreaticoduodenectomy: What really matters?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 22-26.	1.3	17
87	Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. <i>Pancreatology</i> , 2018, 18, 671-677.	1.1	17
88	Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1069-1076.	1.0	17
89	Surgical Resection for Metastatic Tumors in the Pancreas: A Single-Center Experience and Systematic Review. <i>Annals of Surgical Oncology</i> , 2019, 26, 1649-1656.	1.5	17
90	Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. <i>Cancers</i> , 2019, 11, 1998.	3.7	17

#	ARTICLE	IF	CITATIONS
91	The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. <i>Aging</i> , 2020, 12, 24228-24241.	3.1	15
92	Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis via suppression of sirtuin 3 in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 4893-4905.	3.3	15
93	18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. <i>International Journal of Oncology</i> , 2014, 45, 1531-1536.	3.3	14
94	Metabolic tumor burden: A new promising way to reach precise personalized therapy in PDAC. <i>Cancer Letters</i> , 2015, 359, 165-168.	7.2	14
95	The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. <i>Journal of Cancer</i> , 2019, 10, 4123-4131.	2.5	14
96	Differentiation of solid-pseudopapillary tumors of the pancreas from pancreatic neuroendocrine tumors by using endoscopic ultrasound. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 947-953.	1.5	14
97	Molecular epidemiology of rotavirus infections among children hospitalized for acute gastroenteritis in Shanghai, China, 2001 through 2005. <i>Journal of Clinical Virology</i> , 2009, 44, 58-61.	3.1	13
98	Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. <i>Oncology Letters</i> , 2017, 13, 3163-3168.	1.8	13
99	Revised nodal stage for pancreatic neuroendocrine tumors. <i>Pancreatology</i> , 2017, 17, 599-604.	1.1	11
100	Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?. <i>Oncotarget</i> , 2016, 7, 29177-29186.	1.8	11
101	Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. <i>Oncology Letters</i> , 2017, 13, 881-886.	1.8	10
102	Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features. <i>Bioengineered</i> , 2021, 12, 3593-3602.	3.2	10
103	Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. <i>International Journal of Biological Sciences</i> , 2021, 17, 2666-2682.	6.4	10
104	Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. <i>Gland Surgery</i> , 2021, 10, 1564-1575.	1.1	10
105	Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	9
106	Pancreatic cancer: gene therapy approaches and gene delivery systems. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 73-88.	3.1	8
107	AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN. <i>World Journal of Surgical Oncology</i> , 2019, 17, 137.	1.9	8
108	AMR monitoring in microvascular decompression for hemifacial spasm: 115 cases report. <i>Journal of Clinical Neuroscience</i> , 2020, 73, 187-194.	1.5	8

#	ARTICLE	IF	CITATIONS
109	A comprehensive comparison of clinicopathologic and imaging features of incidental/symptomatic non-functioning pancreatic neuroendocrine tumors: A retrospective study of a single center. <i>Pancreatology</i> , 2015, 15, 519-524.	1.1	7
110	Roux-en-Y pancreaticojejunostomy reconstruction after deep enucleation of benign or borderline pancreatic lesions: a single-institution experience. <i>Hpb</i> , 2016, 18, 145-152.	0.3	7
111	Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 163-172.	1.3	7
112	Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprogramming of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 643465.	2.8	7
113	Age and sex specific reference intervals of 13 hematological analytes in Chinese children and adolescents aged from 28Ådays up to 20Åyears: the PRINCE study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1250-1260.	2.3	7
114	Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4591-4608.	2.0	6
115	A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 650266.	2.8	6
116	Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 2031-2048.	3.1	6
117	Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. <i>Frontiers in Oncology</i> , 2021, 11, 640820.	2.8	5
118	Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy. <i>Medical Science Monitor</i> , 2017, 23, 2315-2323.	1.1	5
119	Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. <i>Surgery</i> , 2018, 163, 1080-1089.	1.9	4
120	From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 654660.	4.8	4
121	Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 674897.	2.8	3
122	Is MVD the effective treatment for poorly controlled hypertension?. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 20-25.	1.5	2
123	Mutation and Expression of Gene YY1 in Pancreatic Neuroendocrine Tumors and Its Clinical Significance. <i>Endocrine Practice</i> , 2021, 27, 874-880.	2.1	2
124	Construction of a paclitaxel-related competitive endogenous RNA network and identification of a potential regulatory axis in pancreatic cancer. <i>Translational Oncology</i> , 2022, 20, 101419.	3.7	2
125	Effect and mechanism of miRNA on obstructive sleep apnea in children. <i>Materials Express</i> , 2020, 10, 404-411.	0.5	1
126	Validation and head-to-head comparison of four models for predicting malignancy of intraductal papillary mucinous neoplasm of the pancreas: A study based on endoscopic ultrasound findings. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 1043-1053.	2.0	0

#	ARTICLE	IF	CITATIONS
127	The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	1.3	0